Medical Device Establishment Licence (MDEL)

1. Key takeaways

The MDEL (Medical Device Establishment License) is the establishment licence the SFDA issues to legal entities carrying out medical device activities in Saudi Arabia; different activities such as import, distribution, retail and manufacturing correspond to different licence scopes, and that activity scope should be consistent with the business activities recorded in the commercial registration. The legal basis is Law M/54 and the Implementing Regulation; the procedural basis is MDS-REQ 9 V1.0 (2022-07-31), with quality system requirements linked to the inspection logic of MDS-REQ 10 V1.0 (2022-06-22). The practical estimate of the MDEL fee range is SAR 5,000 to 25,000, depending on factors such as device type, staff experience and employee numbers, plus 15% VAT. GRZAN’s assessment is that the MDEL is designed on the principle of qualifying the enterprise before qualifying the product, so site conditions and staffing carry as much weight as the document list.

• The MDEL regulates the enterprise; the MDMA regulates the product. The two lines are independent and cannot substitute for each other.
• Activity scope must match the commercial registration; mismatches block the licence and later inspections.
• Practical estimate of fees: SAR 5,000 to 25,000 plus 15% VAT, driven by capability and risk exposure rather than product count.
• Procedure under MDS-REQ 9 V1.0; inspections and quality system under MDS-REQ 10 V1.0.
• Check a partner’s MDEL activity scope first when selecting local counterparts.

2. Legal basis

The table below lists the instruments cited for the establishment licence. Items marked as a practical estimate are pending verification against GHAD billing.

3. Expert insights

1. The enterprise and the product are two separate compliance lines. Many manufacturers assume that holding an MDMA is enough to sell, which is not true in Saudi Arabia. The MDMA answers whether the device may circulate; the MDEL answers whether the entity is qualified to import, distribute or retail. The two lines correspond to the definitions of Marketing Authorization and License in Article 1 of Law M/54 and cannot replace each other. The consequence is immediate: if the product is certified but the importer holds no matching MDEL, the shipment stops at port, and a distributor acting beyond its licensed scope, for example licensed only for general consumables while distributing implantable or temperature-controlled IVD products, is out of scope. GRZAN recommends making the counterpart’s MDEL activity scope the first due diligence item when choosing a local partner.

2. Writing the activity scope into the commercial registration makes the two registries interlock. The point that the MDEL activity scope must be written into the commercial registration reflects a structural feature of Saudi regulation: the commercial registration, managed by the commerce authorities, and the establishment licence, managed by the SFDA, must point to the same set of business activities. If the registration says general trading while the MDEL application covers medical device import and distribution, the mismatch obstructs both the application and later inspections. Conversely, when the company expands into new device categories, the commercial registration should be amended first and the MDEL second. This is especially critical for Chinese manufacturers setting up a Saudi subsidiary: state the activities fully at registration, and handle additions later through change procedures (practical estimate).

3. The wide fee range points to capability, not products. The practical estimate of the MDEL range is SAR 5,000 to 25,000, a fivefold spread. The stated determinants, device type, staff experience and employee numbers, show that the pricing weighs the operator’s capability and risk exposure rather than product count: the higher the device risk, the stronger the staff qualifications and the larger the organization, the higher the cost. Budgeting therefore cannot transfer another company’s paid amount onto itself. GRZAN stress-tests MDEL costs at the top of the range at project initiation and separately lists hidden investments such as site renovation, temperature control equipment and staff training, which often exceed the licence fee itself. All fees carry an additional 15% VAT.

4. Interfaces with manufacturing licensing and the inspection system. Where manufacturing takes place in Saudi Arabia, MDS-G011 V2.0 divides the paths into full manufacturing, branch manufacturing and contract manufacturing, requiring a medical device manufacturing licence (see MDS-REQ 9) and an ISO 13485:2016 certificate issued by an SFDA-recognized conformity assessment body (CAB) (see MDS-REQ 10). Importers and distributors carry no manufacturing path duties but still fall within the MDS-REQ 10 inspection framework and bear reporting duties under MDS-REQ 11 V2.0, including designating an SFDA contact person. Projects on the reliance pathway (MDS-G030 V1.0) are the same: reliance simplifies product technical review, not establishment licensing.

For establishment licence site conditions and review focus, see https://www.grzan.cn/regulations/saudi/warehouse-storage-and-transport-requirements-35 ; for SFDA inspection logic, see https://www.grzan.cn/regulations/saudi/sfda-inspection-and-market-surveillance-48 .

4. Practical recommendations

• Define the activity scope first: establish whether the activity is import, distribution, retail or manufacturing, list device risk classes and categories, then start the licence application.
• Align the commercial registration: compare the Saudi entity’s registered activities word for word with the MDEL application scope; amend the registration first if they differ.
• Staffing and organization: assign personnel with relevant experience per MDS-REQ 9, designate the SFDA contact person, and keep employment contracts, CVs and training records.
• Quality system documentation: build QMS documentation linked to MDS-REQ 10; importers and distributors should at minimum cover purchasing acceptance, storage and transport, traceability and recall.
• Budget at the top of the range: stress-test MDEL costs at the upper end of SAR 5,000 to 25,000 (practical estimate) plus 15% VAT, listing site renovation separately.
• Payment and records: pay via SADAD per the GHAD billing amount and keep receipts; register the licensed activity scope and validity in the ledger.
• Register changes before licensing: when adding device categories, amend the commercial registration first, then apply for an MDEL scope change, avoiding out-of-scope operation.
• Official technical support: for questions on licence conditions and document lists, use SFDA free channels first, call centre 19999 and md.rs@sfda.gov.sa.

5. Verification checklist

• □ Specific activity types (import, distribution, retail, manufacturing) and device categories defined
• □ The Saudi entity’s commercial registration covers the intended MDEL activity scope
• □ Current MDS-REQ 9 downloaded and condition list compared item by item
• □ Staffing and the SFDA contact person confirmed and documented
• □ Quality management system documentation established, covering acceptance, storage and transport, traceability and recall
• □ MDEL costs estimated across the SAR 5,000 to 25,000 range (practical estimate) plus 15% VAT
• □ SADAD payment receipts archived; licence number and validity registered
• □ For manufacturing, ISO 13485:2016 certificate confirmed as issued by an SFDA-recognized CAB
• □ Partner’s MDEL activity scope confirmed where a local importer is engaged
• □ Current version numbers of MDS-REQ 9 and MDS-REQ 10 checked on the SFDA website

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team coordinates Saudi Authorized Representative arrangements, import licences, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com